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CD8+ cells from healthy HIV-1-infected individuals suppress human immunodeficiency virus (HIV) replication in infected cells by a non-
cytotoxic mechanism. This activity is associated with the production of a soluble CD8+ cell antiviral factor (CAF) that inhibits viral replication at
the level of transcription. Strong CD8+ cell non-cytotoxic anti-HIV responses (CNARs) correlate with an asymptomatic state and long-term
survival of HIV-infected individuals. This antiviral activity is lost when the infected individual advances to disease. In attempts to define the gene
(s) mediating CNAR we have evaluated differential gene expression between CD8+ cells from infected subjects with high CNAR and CD8+ cells
from uninfected controls that lack this activity. The expression analysis, using the Affymetrix GeneChip Human Genome U133 Set, indicated that
18% of the genes were differentially expressed (DE) of which 9.2% were up-regulated. A total of 568 genes were up-regulated with a >2.0-fold
difference in expression levels and a >50% concordance of difference call. Stringent selection criteria narrowed down the list to 52 up-regulated
‘high confidence genes’ (≥75% concordance). These genes function in a wide variety of cellular processes and include 13 associated with
immunologic activity.
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CD8+ cells from healthy HIV-1-infected individuals can
suppress human immunodeficiency virus (HIV) replication in
infected CD4+ cells without killing the cell (Levy et al., 1996;
Walker et al., 1986). This CD8+ cell non-cytotoxic antiviral
response (CNAR) is not restricted by class I or class II
molecules (Levy et al., 1996; Mackewicz et al., 1998) and is
mediated at least in part by production of a soluble CD8+ cell
antiviral factor (CAF) that inhibits viral replication at the
level of transcription (Copeland et al., 1995; Mackewicz et al.,
1995; Walker and Levy, 1989). CAF is not retrovirus-specific
and lacks identity with other known cytokines, including⁎ Corresponding author. Fax: +1 415 476 8365.
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doi:10.1016/j.virol.2006.12.007various chemokines with anti-HIV activity (Brinchmann et
al., 1991; Mackewicz et al., 1994b) (for review, see Levy,
2003).
Clinical evidence suggests that CNAR is an innate immune
response that helps prevent viral replication as well as control
virus during the acute infection phase, even before serocon-
version (Levy, 2001; Mackewicz et al., 1994a). High CNAR
correlates with an asymptomatic state and long-term survival
of HIV-infected individuals (Mackewicz et al., 1991; Gomez
et al., 1994; Landay et al., 1993). Loss of CNAR over time is
usually associated with progression to disease; patients who
have developed AIDS do not show this anti-HIV response
(Barker et al., 1998; Gomez et al., 1994; Landay et al., 1993;
Levy et al., 1996; Mackewicz et al., 1991). These findings
suggest that CNAR plays an important role in controlling HIV
infection and is one of the major determinants of a beneficial
clinical course. Moreover, CNAR has been detected in
exposed (high risk) uninfected subjects (within 1 year)
suggesting a role in protection from infection (Stranford et
al., 1999).
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discovery of novel genes or biological functions. In the present
study we have chosen this approach in attempts to identify a
CNAR-associated gene(s). The gene expression profile of
CD8+ cells from HIV-1-infected subjects with high CNAR and
CD8+ cells from uninfected controls that lack this antiviral
activity has been evaluated using high-density oligonucleotide
microarrays (Affymetrix GeneChip Human Genome U133 Set).
The identification of the gene(s) responsible for this natural
anti-HIV response should provide a valuable novel approach for
therapy of infected people.
Results
Acute infection assay for CD8+ cell non-cytotoxic anti-HIV
response (CNAR)
Acute infection assays were performed on CD8+ cells from
four healthy HIV-infected subjects and four seronegative
subjects. After a 5-day co-culture of CD8+ cells with CD4+
cells at a 1:1 cell input ratio, the percentage of suppression was
calculated by comparing the average value of RT activity in
culture fluids from control wells containing replicates (×3) of
infected CD4+ cells grown alone with the average RT activity in
the co-cultures. The average percent of HIV-1 replication was
96% for HIV-infected individuals (high CNAR) and 26% for
seronegative subjects (Fig. 1).
Microarray expression analysis
CD8+ cells' cRNA from four healthy HIV-infected subjects
with strong CNAR and four HIV-seronegative individuals that
lack this activity were hybridized to the Affymetrix GeneChip
Human Genome U133 Set (representing ∼33,000 human
genes, including EST sequences) (Fig. 2). The data were
submitted to gene expression analysis using GeneChip Analysis
Microarray Suite v5, MicroDB v3.0 and Data Mining Tool
Software v3.0.Fig. 1. Percent suppression of HIV-1 replication by CD8+ cells from
seronegative controls and HIV-1 infected subjects with strong CNAR.
Suppression of HIV-1SF33 replication was assessed at day 5 of an acute
infection assay at a 1:1 CD8+ cell/CD4+ cell ratio.Comparison expression analysis (see Materials and
methods), revealed that 18% of the genes were differentially
expressed (DE) of which 9.2% were up-regulated. A total of
568 genes were up-regulated with a >2.0-fold difference in
expression levels and a >50% concordance of difference call.
A ‘Comparison Ranking Test’ using a cut-off value of ≥75%
was used to increase the confidence that the transcripts selected
were indeed DE and to generate a more manageable number of
genes for further analysis (Fig. 3). These stringent selection
criteria narrowed down the list to 69 up-regulated ‘high
confidence genes’. HLA associated genes (which are not
relevant to CNAR) (Levy et al., 1996; Mackewicz et al., 1998)
and 10 sequences with repeats were deleted generating a final
list of 52 genes. 13 of these are associated with immune
responses and three are unknowns (Fig. 3). A summary of the
information gathered for each upregulated gene identified that
includes the Affymetrix probe identification number, gene title,
gene symbol, chromosome location and Entrez reference
number is presented in Table 1.
cRNA from the same pair of subjects (HIV+ and
seronegative controls) used in this study were also hybridized
to the GeneChip Human Genome U95 Set and analyzed using
both GeneChip Analysis Microarray Suite v4.0 (MSv4) and
v5.0 (MSv5). Results obtained using these previous Affymetrix
platforms and analysis software were, in general, very similar to
the results presented in this paper (data not shown).
Functional analysis of the upregulated differentially expressed
genes
The upregulated gene's list was submitted through the
NetAffx Analysis Center and DAVID (see Materials and
methods) to obtain annotations and functional data that will
help in the identification of genes that might be related to
CNAR. The genes could be grouped into four categories (Fig.
4): 27 genes associated with cellular physiological processes
(i.e. cell cycle, motility, apoptosis, biogenesis, proliferation,
metabolism), 13 genes linked to immunological processes
(both cellular and humoral), 9 genes with unknown biological
function (5 of them with defined molecular functions) and 3
unknown genes. The immunology-associated genes included
chemokine ligands 3, 4, and 5 (RANTES), granzyme H and
K, cystatin F, tumor necrosis factor receptor superfamily
member 9, killer cell lectin-like receptor subfamily A,
interleukin 2 receptor alpha, and interferon gamma. Some of
these immunology genes have been previously reported to be
up-regulated in HIV infection (Genin et al., 1999; Ryo et al.,
2000).
The DE list also includes genes involved in a wide range of
cellular physiological processes. Among these was the vascular
cell adhesion molecule (VCAM) that has been associated with
strong CNAR (Diaz et al., 2005). Genes that are not linked to a
biological process include a family with sequence similarity 3
with cytokine-like molecular function and microRNA21 (small
regulatory RNAs). The unknown genes include a hypothetical
protein, FLJ39873, a trophoblast-derived non-coding RNA and
a cDNA FLJ35091 fis clone PLACE6005786.
Fig. 3. The differential gene expression between CD8+ cells from HIV+ subjects with high CNAR and CD8+ cells from uninfected controls that lack this activity was
evaluated using the Affymetrix® GeneChip® Human Genome U133 Set. Expression analysis indicated that 18% of the genes were differentially expressed (DE); 9.2%
up-regulated. Further analysis of DE genes revealed a total of 568 up-regulated genes with a >2.0-fold difference in expression levels and a >50% concordance of
difference call. Stringent selection criteria narrowed down the list to 52 up-regulated ‘high confidence genes’ (≥75% concordance). These genes function in a wide
variety of cellular processes and include 13 immunologic genes.
Fig. 2. Preparation of cRNA for microarray hybridization. Total RNA was isolated and purified from CD8+ cells from HIV+ subjects showing high CNAR and
seronegative control subjects with none or low CNAR using a combined Trizol/RNeasy method. Complementary DNA (cDNA) was synthesized with the SuperScript
Double Stranded cDNA Synthesis Kit. The cDNAwas then subjected to an in vitro transcription (IVT) reaction and the product fragmented to generate RNA fragments
of approximately 35 to 200 bases. Samples were analyzed on 1% agarose gels. See Materials and methods for details.
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Table 1
Differentially expressed genes, ≥75% concordance
Probe set ID Gene title Gene symbol Chromosomal location Entrez gene
1405_i_at Chemokine (C–C motif) ligand 5 CCL5 17q11.2–q12 6352 Entrez gene
200800_s_at Heat shock 70 kDa protein 1A HSPA1A 6p21.3 3303 Entrez gene
200878_at Endothelial PAS domain protein 1 EPAS1 2p21–p16 2034 Entrez gene
201889_at Family with sequence similarity 3, member C FAM3C 7q22.1–q31.1 10447 Entrez gene
202085_at Tight junction protein 2 (zona occludens 2) TJP2 9q13–q21 9414 Entrez gene
202206_at ADP–ribosylation factor-like 7 ARL7 2q37.1 10123 Entrez gene
202265_at Polycomb group ring finger 4 PCGF4 10p11.23 648 Entrez gene
202551_s_at Cysteine-rich transmembrane BMP regulator 1 (chordin-like) CRIM1 2p21 51232 Entrez gene
202760_s_at A kinase (PRKA) anchor protein 2 AKAP2 9q31–q33 11217 Entrez gene
203232_s_at Ataxin 1 ATXN1 6p23 6310 Entrez gene
203868_s_at Vascular cell adhesion molecule 1 VCAM1 1p32–p31 7412 Entrez gene
203946_s_at Arginase, type II ARG2 14q24.1–q24.3 384 Entrez gene
203989_x_at Coagulation factor II (thrombin) receptor F2R 5q13 2149 Entrez gene
204103_at Chemokine (C–C motif) ligand 4 CCL4 17q12 6351 Entrez gene
204529_s_at Thymus high mobility group box protein TOX TOX 8q12.1 9760 Entrez gene
204798_at v-myb myeloblastosis viral oncogene homolog (avian) MYB 6q22–q23 4602 Entrez gene
205114_s_at Chemokine (C–C motif) ligand 3 CCL3 17q11–q21 414062 Entrez gene
206666_at Granzyme K (granzyme 3; tryptase II) GZMK 5q11–q12 3003 Entrez gene
207229_at Killer cell lectin-like receptor subfamily A, member 1 KLRA1 12p13–p12 10748 Entrez gene
207536_s_at Tumor necrosis factor receptor superfamily, member 9 TNFRSF9 1p36 3604 Entrez gene
208690_s_at PDZ and LIM domain 1 (elfin) PDLIM1 10q22–q26.3 9124 Entrez gene
208949_s_at Lectin, galactoside-binding, soluble, 3 (galectin 3) LGALS3 14q21–q22 3958 Entrez gene
209348_s_at v-maf musculoaponeurotic fibrosarcoma oncogene homolog MAF 16q22–q23 4094 Entrez gene
210116_at SH2 domain protein 1A, Duncan's disease SH2D1A Xq25–q26 4068 Entrez gene
210140_at Cystatin F (leukocystatin) CST7 20p11.21 8530 Entrez gene
210321_at Granzyme H (cathepsin G-like 2, protein h-CCPX) GZMH 14q11.2 2999 Entrez gene
210354_at Interferon, gamma IFNG 12q14 3458 Entrez gene
210732_s_at Lectin, galactoside-binding, soluble, 8 (galectin 8) LGALS8 1q42–q43 3964 Entrez gene
211269_s_at Interleukin 2 receptor, alpha IL2RA 10p15–p14 3559 Entrez gene
211503_s_at RAB14, member RAS oncogene family RAB14 9q32–q34.11 51552 Entrez gene
212398_at Radixin RDX 11q23 5962 Entrez gene
213649_at Splicing factor, arginine/serine-rich 7, 35 kDa SFRS7 2p22.1 6432 Entrez gene
214452_at Branched chain aminotransferase 1, cytosolic BCAT1 12pter–q12 586 Entrez gene
214615_at Purinergic receptor P2Y, G-protein-coupled, 10 P2RY10 Xq21.1 27334 Entrez gene
214657_s_at Trophoblast-derived noncoding RNA TncRNA 11q13.1 283131 Entrez gene
215001_s_at Glutamate–ammonia ligase (glutamine synthetase) GLUL 1q31 2752 Entrez gene
216834_at Regulator of G-protein signalling 1 RGS1 1q31 5996 Entrez gene
217147_s_at T cell receptor associated transmembrane adaptor 1 TRAT1 3q13 50852 Entrez gene
219371_s_at Kruppel-like factor 2 (lung) KLF2 19p13.13–p13.11 10365 Entrez gene
220990_s_at Transmembrane protein 49 TMEM49 17q23.2 406991 Entrez gene
223519_at Sterile alpha motif and leucine zipper containing kinase AZK ZAK 2q24.2 51776 Entrez gene
224917_at microRNA 21 MIRN21 406991 Entrez gene
226683_at Sorting nexin-associated golgi protein 1 SNAG1 5q11.2 112574 Entrez gene
228964_at PR domain containing 1, with ZNF domain PRDM1 6q21–q22.1 639 Entrez gene
231776_at Eomesodermin homolog (Xenopus laevis) EOMES 3p21.3–p21.2 8320 Entrez gene
235003_at U2AF homology motif (UHM) kinase 1 UHMK1 1q23.3 127933 Entrez gene
235310_at Germinal center expressed transcript 2 GCET2 3q13.2 257144 Entrez gene
236787_at CDNA FLJ35091 fis, clone PLACE6005786
239002_at asp (abnormal spindle)-like, microcephaly associated ASPM 1q31 259266 Entrez gene
240070_at Hypothetical protein FLJ39873 FLJ39873 3q13.31 201633 Entrez gene
243296_at Pre-B-cell colony enhancing factor 1 PBEF1 7q22.3 10135 Entrez gene
244774_at Phosphatase and actin regulator 2 PHACTR2 6q24.2 9749 Entrez gene
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genes
In order to confirm the differential expression of genes from
the U133 microarray, mRNA expression levels from 37 genes
were measured by kRT–PCR. Of these 37 genes, 23 are involved
in cellular physiological processes, five have been associated
with immunological functions, seven are known genes withunknown biological function, one is a hypothetical protein and
the other is a cDNA clone (Fig. 4).
Seventeen (47.2%) genes demonstrated up-regulation of
mRNA to a statistically significant level (p<0.05) in CD8+ cells
from seven healthy HIV-infected subjects with strong CNAR
compared to CD8+ cells from seven uninfected healthy subjects
who lacked CNAR. Ten of these were part of the twenty-three
genes that play a role in cellular physiological processes. Of the
Fig. 4. Differentially expressed genes classified by biological function. Genes were classified in four main categories: immune response associated genes, genes
associated with cellular physiological processes, genes with unknown biological functions and unknown genes. Information is presented as gene symbol. Refer to
Table 1 for gene title, and additional information. Genes marked in bold were further analyzed by kRT–PCR.
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CST7 and TNFRSF9 were significantly upregulated in the
healthy HIV-infected subjects. Four of the seven genes with
unknown biological function (FAM3C, TJP2, TMEM49 and
GCET2) were significantly up-regulated. The unknown clone
screened (FLJ35091 fis, clone PLACE6005786) was also
significantly up-regulated in the CD8+ cells from the seven
healthy HIV-infected subjects compared to the CD8+ cells from
seven healthy uninfected subjects. All of these genes were found
to be consistently up-regulated by greater than a 2-fold increase
in mRNA expression (Fig. 5). Four of the seventeen genes
showed greater than a 5-fold increase in expression (EOMES,
SNAG1,GCET2, VCAM1), and two of the seventeen had greater
than a 10-fold increase in expression (EOMES,VCAM1) (Fig. 5).
Discussion
In an attempt to define CNAR, we evaluated, using
Affymetrix® GeneChip, the differential gene expression
between CD8+ cells from infected subjects with high CNAR
and CD8+ cells from uninfected controls that lack this activity
(Fig. 1). We conducted these studies using the Affymetrix
GeneChip® U133 with improved annotation, classification and
sequence quality (Affymetrix I. Array Design for the Gene-
Chip® Human Genome U133 Set, Santa Clara, CA, 2001) (Fig.
2). Comparison ranking analysis narrowed down the up-
regulated candidate gene's list to 52 “high confidence” genes
that overlap when all possible combinations of comparisons
analyses for the HIV-infected individuals and the uninfected
controls were generated (≥75% concordance) (Fig. 3). These
genes, involved in a wide range of cellular processes, included
13 immunology-related genes and 3 unknowns (Fig. 4). The
identification of genes that have been previously reported to beup-regulated during viral diseases and HIV infection (e.g. IFN-
γ, CCL 3–5) gave us confidence in our analysis approach.
Furthermore, some of the up-regulated genes (e.g. VCAM1)
overlapped with genes identified using the Stanford Lympho-
chip® in separate studies conducted by our laboratory (Diaz et
al., 2005).
The expression profile of the selected identified genes was
confirmed using kinetic reverse transcriptase–PCR (kRT–
PCR) comparing gene mRNA expression in CNAR+ and
CNAR−CD8+ cells. Seventeen out of 36 genes screened
(47.2%) were found to be consistently up-regulated by greater
than a 2-fold in the HIV-positive subjects showing high
CNAR activity (p<0.05) (Fig. 5). In particular, EOMES,
SNAG1, VCAM1 and GCET2-1 showed greater than a 5-fold
increase in expression.
The eomesodermin homolog gene (EOMES) is induced in
effector CD8 (+) T cells in vitro and in vivo. EOMES expression
is sufficient to bring up functions of effector CD8 (+) T cells,
including interferon-gamma perforin and granzyme B (Pearce et
al., 2003). Some studies suggested that it is likely to act as a key
regulatory gene in the development of cell-mediated immunity
(Pearce et al., 2003). SNAG1 is a member of the sorting nexin
family and is involved in intracellular trafficking. The specific
function of this protein has not been determined (Entrez Gene
ID: 112574). The finding of the VCAM gene significantly up-
regulated in this study confirms previously reported data on the
up-regulation of this gene associated with CNAR (Diaz et al.,
2005).
A notable gene is GCET2 also termed HGAL (human
germinal center-associated lymphoma). This gene is mainly
expressed in germinal center B cells and is stimulated
specifically by the interleukin-4 (IL-4). It encodes a cytoplasmic
protein of 178 amino acids that contains an immunoreceptor
Fig. 5. Fold increase in mRNA expression. Out of the 36 genes tested, 17 (47.2%) were found to be consistently upregulated by kRT–PCR. All showed greater than a
2-fold increase in mRNA expression. Four of the seventeen genes showed greater than a 5-fold increase in expression (GCET2, SNAG1, EOMES, VCAM1), and two of
the seventeen had greater than a 10-fold increase in expression (EOMES, VCAM1).
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GCET2 was strongly correlated with clinical outcome in diffuse
large B-cell lymphoma (DLBCL) patients (Lossos et al., 2003).
Studies found that patients with DLBCL expressing high levels
of GCET2 mRNA demonstrate significantly longer overall
survival than patients with low expression of the gene (Lossos et
al., 2003). Therefore, the finding of high expression of GCET2
in peripheral CD8+ Tcells fromHIV-1 subjects with high CNAR
merits further evaluation.
FAM3C could be another candidate for additional investiga-
tion in CNAR. It belongs to a novel cytokine-like gene family
(Zhu et al., 2002) but its biological function has yet to be
determined. An unknown cDNA clone screened (FLJ35091
fis, clone PLACE6005786) was also significantly up-regulated
in the CD8+ cells showing CNAR. Information found at the
National Center for Biotechnology Information (NCBI; www.
ncbi.nlm.nih.gov) regarding this cDNA clone suggests that it is
expressed in lymph nodes. The protein and function has not
yet been determined. Studies to define the association of this
unknown protein with CNAR should also be considered.
The immunology response-related genes showing greater
than 2-fold increase in mRNA expression were CST7 (leuko-
cystatin) and tumor necrosis factor receptor superfamily,
member 9 (TNFRSF9). CST7 encodes for cystatin F, which is
a cysteine protease inhibitor that is found in peripheral blood
cells and spleen. TNFRSF9 is a member of the tumor necrosis
factor (TNF) receptor families which are important regulators of
a wide variety of physiologic processes and play a pivotal role in
the regulation of immune responses.The rest of the genes showing greater than 2-fold increase in
mRNA expression are involved in transcription regulation
(EPAS1, TOX, PCGF4, MAF), nitric oxide synthesis (ARG2),
response to oxidative stress (PDLIM1), organization of
epithelial and endothelial intercellular junctions (TJP2) and
neurogenesis (CRIM1). They are likely not directly associated
with CNAR but might be indicative of an activated immune
system due to chronic infection.
In summary, using the Affymetrix GeneChip U133 we were
able to identify 52 “high confidence” genes that were up-
regulated in CD8+ cells from infected subjects with high CNAR
when compared to CD8+ cells from uninfected controls that lack
this activity. Analysis by kRT–PCR allowed us to identify
candidate genes for further analysis to determine their relevance
to CNAR. The identification of the gene(s) responsible for this
natural anti-HIV response should provide a valuable approach
for the treatment of HIV-1-infected people.
Materials and methods
Study subjects
Four healthy HIV-infected subjects with strong CNAR and
four HIV-seronegative individuals that lack this activity were
chosen for this study. The HIV-infected subjects were males,
with an average age of 48, and average number of years infected
of 15. None had received antiretroviral treatment. Seronegative
individuals were also males with an average age of 55 years. All
participants came from the San Francisco Bay Area. This study
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CD8+ cell subset purification
Heparinized whole blood samples were collected from
healthy HIV-1-infected subjects by venipuncture. Blood from
uninfected subjects was obtained through the Blood Centers of
the Pacific (San Francisco, CA, USA). Peripheral blood
mononuclear cells (PBMC) were obtained from the blood by
Ficoll/Hypaque (Sigma Chemicals, St. Louis, MO, USA)
gradient separation (Castro et al., 1988). The CD8+ cellular
fraction was purified from the PBMC by immunomagnetic
(IM) bead separations (Miltenyi Biotech, Auburn, CA, USA)
(Diaz et al., 2005). The CD8 monoclonal antibody was
directed against the α chain. Flow cytometry indicated that the
isolated CD8+ cell population was >97% CD3+. Thus, a very
small contamination with other cell types was possible but
would not have greatly affected the results. The cells were
cultured at a density of 3×106 cells/ml in a complete RPMI
1640 medium (Mediatech Cellgro, VA, USA) consisting of
10% (vol./vol.) heat-inactivated (56 °C, 30 min) fetal bovine
serum (FBS) (Gibco-BRL, Gaithersburg, MD, USA), 1%
antibiotics (100 units/ml penicillin and 100 μg/ml streptomy-
cin), 2 mM glutamine, and 100 units/ml recombinant IL-2
(generously provided by Glaxo Wellcome, Triangle Park, NC,
USA).
In vitro CD4+ cell infection
The CD4+ cellular fraction was purified from the PBMC
from healthy donors by IM bead separations. The cells were
stimulated with phytohemagglutinin-leucoagglutinin (PHA-L)
(Sigma) for 3 days (3 μg/ml), washed, and treated with poly-
brene (2 μg/ml) (Sigma) for 30 min. The cells (3×106 cells/ml)
were infected with 10,000 tissue culture 50% infectious dose
(TCID50) of the HIV-1SF33 isolate (Mackewicz et al., 1995).
This cytopathic, β-chemokine-insensitive virus has been
standardized in our laboratory so that the input used results in
substantial virus replication within 7 to 9 days. After 1 h, these
in vitro infected cells were washed to remove free virus and
resuspended at a concentration of 2×106 cells/ml in the
complete RPMI 1640 medium.
Acute infection assay to measure the CD8+ cell non-cytotoxic
anti-HIV response (CNAR)
CNAR activity was evaluated using the acute infection
assay (Mackewicz et al., 1991). Briefly, HIV-1SF33-acutely
infected CD4+ cells, plated in 12-well plates at 106 cells/well,
were mixed with either CD8+ cells from HIV-infected
subjects or CD8+ cells from the uninfected controls at a 1:1
CD8+ cell /CD4+ cell input ratio. Cultures, in RPMI 1640
complete medium, were incubated for 5 days at 37 °C. The
extent of viral replication was measured in culture fluids by
reduction in particle-associated reverse transcriptase (RT)
activity (Hoffman et al., 1985) at days 3 and 5. Thepercentage of suppression was calculated by comparing the
average value of RT activity in culture fluids from control
wells containing the infected CD4+ cells grown alone with
the average RT activity in fluids from wells containing the co-
culture of CD8+ and CD4+ cells.
For RNA extraction, the CD8+ cells were removed from the
co-culture at day 5 by IM bead separation, snap frozen in liquid
nitrogen and stored at −70 °C. CD8+ cell samples from HIV-
infected subjects were used if ≥90% of virus replication was
reduced in comparison to control HIV-infected CD4+ cells
cultured alone. CD8+ cells from uninfected subjects showed
≤25% reduction in virus replication and served as the CNAR
negative controls.
cRNA preparation
Total RNA was isolated and purified from both sets of
CD8+ cells using a combined Trizol/RNeasy (Qiagen Inc.,
Valencia, CA, USA) method. Briefly, total RNA was
extracted from 10×106 CD8+ cells using 1 ml of Trizol
reagent (Invitrogen Corp., Carlsbad, CA, USA) and 0.2 ml
of chloroform. The aqueous phase was then transferred to an
RNeasy column (RNeasy Mini Kit; Qiagen) for RNA
cleanup per manufacturer's protocol. Complementary DNA
(cDNA) was synthesized with the SuperScript Double
Stranded cDNA Synthesis Kit (Invitrogen) using an oligo
(dT) primer containing the T7 RNA polymerase site. The
cDNA was then subjected to an in vitro transcription (IVT)
reaction using the T7 RNA polymerase to generate a biotin-
labeled complementary RNA (cRNA) (Enzo BioArray High
Yield RNA Transcript Labeling kit, Enzo Life Sciences Inc,
Farmingdale, NY, USA) according to the manufacturer's
instructions. The IVT product was then purified (RNeasy
Mini Kit; Qiagen) and fragmented for 35 min at 94 °C in a
Tris–acetate buffer containing magnesium acetate (MgOAc)
and potassium acetate (KOAc) to generate RNA fragments
of approximately 35 to 200 bases. Samples were analyzed on
1% agarose gels.
Microarray hybridization and scanning
The quality and labeling efficiency of the fragmented cRNA
(∼50 μg) from four discordant pairs (HIV-infected/uninfected
subjects) was assessed using the GeneChip® Test3 Arrays
(Affymetrix Inc., Santa Clara, CA, USA). The target cRNAwas
then hybridized to the GeneChip® Human Genome U133 Set
(Affymetrix) comprising two microarrays (U133A and U133B)
representing ∼33,000 human genes (including EST sequences).
Hybridized probe arrays were washed and stained with a
phycoerythrin–streptavidin conjugate on the GeneChip® Flui-
dics Station 400 following the manufacturer's instructions.
GeneChip® probe arrays were then scanned at 488 nm in the
Agilent GeneArray® Scanner to generate images containing
intensity data for each probe cell on the arrays. Hybridization
and scanning of the probe arrays was done at the General
Clinical Research Center (GCRC) Core Facility, San Francisco
General Hospital, San Francisco, CA.
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The microarray analysis was performed using the GeneChip®
Analysis Microarray Suite v5.0 (MSv5), the MicroDB® v3.0
software and the Data Mining Tool v3.0 (DMT) software
(Affymetrix). Data was first analyzed following the MSv5
platform for array analysis described in the Affymetrix®
Microarray Suite v5.0 User's Guide. Briefly, microarray images
(.dat files) were visually inspected for non-specific hybridization.
Background and “noise” were corrected for each array. The cell
intensity files (.cel file), generated automatically from the .dat
files, were submitted to “absolute and comparison expression”
analyses using the default values. The “absolute expression”
analysis generated a “signal value” (relative to the abundance of a
transcript) and a “detection call” (indicating whether the transcript
was detected (P=present), undetected (A=absent), or at the limit
of detection (M=marginal)) for each transcript represented in the
U133 arrays. It also calculated a p-value associated with the
“detection call” using a “one-sided Wilcoxon's signed rank test”.
Before running the comparison expression analysis, the arrays
(HIV-infected, n=4/uninfected subjects, n=4) were scaled to the
same target intensity (default) to allow a direct comparison
between the groups. The “comparison expression” analysis
generated a “signal log ratio” for each transcript (relative change
in the expression level of a transcript between baseline (uninfected
subjects) and experimental (infected subjects) arrays) using the
“one-step Tukey's biweight method. A signal ratio of 1 (log2=1)
is equivalent to a 2-fold change. A “change call”, with its
associated p-value (“Wilcoxon's signed rank test”) was also
calculated indicating if the change in transcript level was in-
creased (“I”), decreased (“D”) or did not change (NC) relative to
the baseline value.
To identify differentially expressed genes, expression
analysis data were published into MicroDB v3.0 and further
analyzed with DMT v3.0. Transcripts were selected if they met
the following criteria: “detection call”=“P” and “signal log
ratio” ≥1 (fold change ≥2). Genes or transcripts fulfilling the
above criteria were subsequently filtered by “change call”,
either “I” or “D”, thus generating two separate gene lists. Each
list was further analyzed using a “Comparison Ranking Test”.
This method, which performs a “count and percentage analysis
“generated all possible combinations of comparison analyses
across the data (experiments or replicates) to determined the
consistency or “concordance “of “change calls”. The highest the
“concordance” (%), the highest the confidence that the
transcript was indeed differentially expressed. We selected a
cut-off value of 75%. The identified differentially expressed
genes were then grouped by gene families and/or functional
classes (biological/molecular function) using the resources pro-
vided through the NetAffx Analysis Center (www.affymetrix.
com) (Liu et al., 2003) and DAVID (http://apps1.niaid.nih.gov/
david/upload.asp) (Dennis et al., 2003).
Quantitative RT–PCR
RNA concentration was determined by spectrophotometry
and adjusted to a concentration of 200 ng/μl. About 500 ng oftotal RNA was reverse transcribed using 250 U of murine
leukemia virus RT (Invitrogen) in 1× Amplitaq buffer
(Applied Biosystems, Foster City, CA, USA) supplemented
with 7.5 mM MgCl2 with 5 μM random hexamers
(Invitrogen), 1 mM each of dNTPs (Invitrogen) and 40 U
of RNase inhibitor (Promega, Madison, WI, USA). The
reaction mixture was incubated at 25 °C for 10 min, 48 °C
for 40 min, and 95 °C for 5 min. About 5 μl of a 1:10
dilution of the RT reaction was subjected to PCR using the
GeneAmp 5700 Sequence Detection System, SYBR Green
PCR Master Mix (Applied Biosystems), and 4 μM primer
mix in a 25 μl reaction. Cycling conditions were as follows:
initial denaturation at 95 °C for 10 min followed by 50 cycles
at 95 °C for 15 s, and 60 °C for 1 min. Primer pairs from
each individual gene were designed using OIigo Primer
Analysis Software v6 (Molecular Biology Insights, Cascade,
CO, USA). The primer sequences were subject to BLAST
analysis to confirm their specificity for a single gene. The
generation of a single PCR product by each primer pair was
tested using the Universal Human Reference RNA (Strata-
gene, La Jolla, CA, USA). The reverse transcription and PCR
reactions were conducted as described above. Primer
sequences for each transcript are available from the authors.
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